Recent Advances in the Diagnosis and Management of Herpetic Keratitis by Nowińska, Anna
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Recent Advances in the Diagnosis 




The chapter is focused on one of the major cause of keratitis - Herpetic keratitis, 
its epidemiology, natural course, clinical forms, prognosis, diagnosis and treatment. 
The estimated global incidence of HSV keratitis is roughly 1,5 million, including 
40,000 new cases of each year. Patients are usually affected in the early decades of 
live, therefore the disease has a severe impact on quality of life and quality of vision 
in young, productive adults. The author describes the detailed corneal character-
istics, provides slit lamp photographs, optical coherence tomography scans and con-
focal microscopy results of different forms of the HSV keratitis: epithelial, stromal, 
necrotizing and endothelial. The chapter also discusses recent methods of diagnosis 
based on PCR testing as well as established and future methods of treatment based 
on the latest research results.
Keywords: HSV keratitis, Herpes simplex virus, confocal microscopy,  
optical coherence tomograpy
1. Introduction
Human herpesviruses, which include HSV-1 (Herpes simplex virus type-1), 
HSV-2 (Herpes simplex virus type-2), HZV (Herpes zoster virus), EBV (Epstein–
Barr virus), CMV (Cytomegalovirus), HHV-6 (Human herpesvirus-6), HHV-7 
(Human herpesvirus-7), HHV-8/KSHV (Human herpesvirus-8, Kaposi’s sarcoma-
associated herpesvirus) are the causative factor of various diseases, including 
mononucleosis, roseola, chickenpox and many forms of ocular involvement, such as 
conjunctivitis, blepharitis, keratitis, uveitis and retinitis. The common features of all 
human herpesviruses include a double-stranded DNA genome, a 20-faceted icosa-
hedral capsid, a surrounding proteinaceous tegument, and an external glycoprotein-
laden lipid envelope. All herpesviruses are able to achieve a state of the latency, where 
the virus remains inactive in cells and occasionally reactivates. Recurrence could be 
described as the most characteristic feature of corneal infections caused by HSV, sub-
sequently leading to visual impairment and blindness. According to epidemiological 
data, HSV keratitis remains a leading infectious cause of blindness in the world. The 
estimated global incidence of HSV keratitis is roughly 1,5 million, including 40,000 
new cases of each year. Additionally the recurrence rate is high. It was estimated 
as 9.6% at 1 year, 22.9% at 2 years, and 63.2% at 20 years after the first episode of 
documented HSV keratitis [1–4]. Also the worldwide seroprevalence rate is high and 
estimated above 50%, but recently it was reported declining in the United States [5].
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In this chapter we will focus on Herpes simplex virus 1 keratitis - the detailed 
corneal characteristics based on slit-lamp examination, optical coherence tomogra-
phy scans and confocal microscopy results. The chapter also discusses recent meth-
ods of diagnosis based on PCR testing as well as established and future methods of 
treatment based on the latest research results.
2. Pathogenesis of the HSV keratitis
General pathogenesis of herpesvirus infections include: active viral replication, 
state of latency and reactivation. Primary infection, usually in the childhood could 
be asymptomatic, oral, but also could affect upper respiratory track or ocular surface 
in the form of the conjunctivitis or blepharoconiunctivitis. After a primary infec-
tion, HSV-1 begins a life-long latency in the trigeminal ganglia, where abundant 
viral RNAs are constantly produced. In order to establish latency, HSV-1 has evolved 
several mechanism to evade the host immune response. The process is complex based 
on HSV-1 several viral proteins targeting multiple steps of the cellular DNA-sensor-
mediated antiviral signal pathway of the host. Moreover, it is believed, that viral pro-
tein activation varies between immediate period after infection and the late phase of 
infection. Inhibition of the type I interferon (IFN-I) activity has been described as the 
main pathogenetic pathway of downregulating the host immune response. Numerous 
mechanism including: inhibiting nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-κB) activation, modulating interferon regulatory factor 3 (IRF3), 
interferon regulatory factor 7 (IRF7) or stimulator of IFN genes (STING) function 
were identified. Recently a broad attention was brought to the HSV-1 immediate early 
(IE) protein infected-cell polypeptide 0 (ICP0), which is an E3 ubiquitin ligase, a 
nuclear phosphoprotein that was described to play an essential role in inhibition of 
IFN-I production through IRF7 protein expression reduction, thus promoting viral 
replication, latency, and reactivation. Certain triggering agents, physiological and 
environmental stress, including ultraviolet exposure, fever, injury, hormonal disrup-
tion or immunosuppression could cause viral reactivation in the tissues innervated 
by the trigeminal ganglion, causing different forms of the HSV keratitis: epithelial, 
stromal or endothelial. Epithelial keratitis is the most common form of HSV keratitis, 
but the recurrence infection may also affect other corneal layers. Recurrence varies 
in frequency between subjects and throughout the life and could cause irreversible 
corneal damage and decrease in visual acuity, ranging from superficial opacities to 
serious complications such as corneal perforation and endophthalmitis [6–10].
3. Diagnosis
The diagnosis of HSV keratitis is mainly based on the presence of typical uni-
lateral corneal lesions on the slit lamp examination. However, the clinical diagnosis 
may be guided by modern imaging techniques, such as optical coherence tomog-
raphy or confocal microscopy. Also, laboratory testing including polymerase chain 
reaction (PCR) and novel techniques based on multiplex dot hybridization (MDH) 
assay or immunochromatographic assay (ICGA) may serve as a potential guide in 
the diagnostic process.
3.1 Symptoms
Patients symptoms depend on the clinical form and stage of the disease. Primary 
infection may be asymptomatic. Recurrent infections symptoms include: foreign 
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body sensation, ocular or ocular adnexa pain, lacrimation, photophobia, decreased 
vision and conjunctival hyperemia. Symptoms are usually not specific. Although, 
patient with recurrent keratitis are aware of the symptoms of the recurrent kerati-
tis, which allows for the rapid referral and treatment. Patients with neutrotrophic 
keratitis due to HSV keratitis may experience only mild symptoms despite the 
advanced corneal involvement.
3.2 Slit lamp examination/clinical forms
Herpetic keratitis is usually classified by anatomical localization in regards to 
affected corneal layers. Although the inflammation process may overlaps different 
layers. Also, recurrent keratitis is not only limited to one layer and can subsequently 
affect different corneal parts [11, 12].
3.2.1 Epithelial keratitis
Epithelial keratitis is the result of the active HSV replication in corneal, epi-
thelial cells. The most characteristic form is the dendritic ulcer containing small 
branches with terminal bulbs. The borders of the branches are raised above the 
corneal surface. The ulcer may be single or multiple. Several dendritic ulcers may 
form a geographic ulcer, especially in patients with immune system deficiency, 
treated with topical steroids or in the long course of the disease. Other forms of epi-
thelial involvement include punctate keratitis or epithelial vesicles. On the slit lamp 
examination, epithelial defects stain with fluorescein and become evident with the 
use of a blue filter (450 nm) with or without additional yellow barrier filter between 
1 and 3 min after the dye instillation. Other symptoms in epithelial keratitis may 
include: bulbar conjunctival and limbal hyperaemia, subepithelial stromal edema at 
the ulcer site and subepithelial infiltration of inflammation cells. Epithelial keratitis 
in the form of the dendritic ulcer may also be present in the stromal recurrent 
keratitis. However, if multiple recurrence occur, the neurotrophic ulcer is definitely 
more probable clinical form compared to the dendritic ulcer. Characteristic features 
of the different forms of the epithelial keratitis are presented in Figure 1.
3.2.2 Stromal keratitis
Stromal involvement in case of herpetic keratitis develops on an immune related 
basis. Inflammatory response to the HSV is connected with the activation and 
infiltration of myeloid-derived cells, CD4+ T-cell and NK cells. Stromal inflamma-
tion may lead to the reduced corneal transparency, persistent scar formation, may 
also cause an irreversible tissue pathology including vascularization and stromal 
necrosis. The inflammation process is often accompanied by stromal localized or 
extensive corneal edema and a mild anterior chamber reaction. Several recurrences 
may lead to the lack of the corneal innervation. Moreover, the severity of disease 
may increase with each subsequent episode, as inflammatory reaction becomes 
stronger despite no detectable viral activity.
Throughout the years multiple clinical forms in terms of stromal keratitis were 
described, being the source of confusion in diagnostic terminology, including: 
immune stromal, interstitial, necrotizing, nonnecrotizing, disciform, focal, multifo-
cal, diffuse. This could contributed to misdiagnosis, especially in early phases of the 
disease and misapplications of therapy in clinical practice. For example, in Japan, 
“disciform” keratitis is considered a type of stromal keratitis. “Immune stromal” term 
also is misleading, suggesting, that other forms of HSV stromal keratitis do not involve 
immune reaction. That is why a simplified classification of the stromal keratitis was 
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proposed, dividing the keratitis into two distinct forms: stromal with and without 
an overlying epithelial ulceration. Stromal keratitis without ulceration, is the more 
common form, historically described as “nonnecrotizing,” “immune-stromal,” and 
“interstitial.” Stromal keratitis with ulceration is the effect of severe inflammation 
and relates to historical description of “necrotizing” keratitis. The form with the ulcer 
is more probably the result of stromal HSV reactivation, although the neurotrophic 
pathogenesis of the ulcer also cannot be ruled out. This terminology could be easily 
implemented in clinical practice and allows ophthalmologists to properly counsel 
patients regarding diagnosis, treatment and prognosis [12]. Figure 2 contains clinical 
presentations of the range stromal keratitis. Figure 3 present a clinical case of a patient 
diagnosed with stromal keratitis with ulceration throughout the treatment process.
Marginal keratitis is a special, rarely occurring form of stromal and epithelial 
keratitis. Clinically it is difficult to differentiate from other forms of marginal kerati-
tis, thus laboratory testing may be helpful in establishing the final diagnosis. The lack 
of corneal sensitivity could also be used as a clinical clue in differential diagnosis.
3.2.3 Endothelitis
This form is believed to be a result of endothelial cells viral infection coexisting 
with immune reaction. Usually, the endothelitis is localized with a distinct area of 
Figure 1. 
Representative images of the slit-lamp photograph of the epithelial HSV keratitis. (A, B) Central, single 
dendritic ulcer before and after fluorescein installation. Branches with terminal bulbs visible. (C, D) Single 
dendritic ulcer with branches are raised above the corneal surface. Stromal haze accompanying the ulcer is 
noticeable. (E) Multiple, small dendritic ulcers visible under blue light after fluorescein installation. (F) 
Geographic, paracentral ulcer visible under blue light after fluorescein installation.
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the corneal edema. Therefore, it was historically described as disciform endothe-
lial keratitis. Focal keratic precipitates, as well as Descemet membrane folds may 
be spotted in the affected area. Rarely, diffuse stromal edema, accompanied by 
trabeculitis with elevated intraocular pressure occurs. Various range of endothelitis 
is presented in Figure 4.
3.2.4 Neurotrophic ulcer/metaherpetic ulcer
This should be considered as a different entity, because there is no virus activation 
in case of neurotrophic ulcer. Also, the inflammation level compared to active HSV 
keratitis is lower. The most characteristic feature is the absence of corneal innervation 
and a non-healing corneal ulcer with smooth margins. As HSV keratitis alters the 
corneal nerves, the disease is one of the leading causes of neurotrophic keratopathy, 
Figure 2. 
Representative images of the slit-lamp photograph of eyes with the different involvement of the stromal 
keratitis or with corneal scars following HSV keratitis. (A) Paracentral stromal infiltration with profound, 
active limbal vascularization. (B) Epithelial, dendritic ulcer accompanied by active stromal keratitis with 
vascularization. (C) Central stromal scarring with deep, peripheral vascularization. (D) Stromal haze 
in the course of recurrent stromal HSV keratitis. (E) Excessive corneal scarring with significant, deep, 
peripheral vascularization. (F) Significant area of corneal scar accompanied by lipid keratopathy and deep 
vascularization.
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among others, such severe dry eye disease, ocular burns or denervation post neuro-
surgical procedures. The pathogenesis is complex and include toxicity from antiviral 
medications, lack of nerve growth factors, the nerve damage as a result of recurrent 
keratitis. The neurotrophic keratitis is characterized by three stages of the severity: 
stage 1, punctate epithelial keratitis (PEK); stage 2, a nonhealing corneal persistent 
epithelial defect (PED); and stage 3 involving stromal involvement in the form of the 
neurotrophic ulceration. Possible accompanying signs are neovascularization, stromal 
haze and scarring. Consequently corneal poor ability to heal may result in corneal melt-
ing, prolonged ulceration, corneal perforation and endophthalmitis. A corneal sensitiv-
ity test is essential to confirm a diagnosis of neurotrophic keratitis. The test should be 
performed in regards to corneal location (central, peripheral), using a cotton-tipped 
swab or an esthesiometer. Figure 5 presents forms of the neurotrophic keratitis.
Figure 3. 
Slit-lamp photographs presenting the follow up of a 65-year old patient with HSV stromal keratitis with 
ulcer. (A, B) Baseline, at diagnosis. Recurrent stromal keratitis with significant ulcer, stromal infiltration, 
vascularization and corneal thinning. Patient treated with the combination of antiviral medication (Oral 
acyclovir 800 mg, 5 times daily at baseline; topical 3% acyclovir ointment 4 times daily) combined with 0,1% 
dexamethasone (3 times daily) and preservative free lubricant eye drops (hourly). (C, D) At 1 month in the 
course of treatment. Significant decrease of the area of the ulcer. Remaining significant corneal infiltration 
with vascularization. Oral acyclovir dosage tapered gradually to 400 mg 4 times daily. Topical acyclovir 
discontinued. (E, F) At 3 months in the course of treatment. Ulcer healed completely. Punctate keratopathy 
visible under blue light. Decreased stromal infiltration, but stromal haze, thinning and vascularization visible. 
Oral acyclovir and 0,1% dexamethasone doses tapered very carefully within months to prevent active keratitis 
recurrence. Patient was recommended a frequent use of the preservative free eye lubricant drops.
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3.3 Confocal microscopy
Confocal microscopy (IVCM - in vivo confocal microscopy) is the imaging 
technique developed to analyze corneal layers with the resolution of 1 μm. Imaging 
with confocal microscopy is used in clinical practice in differential diagnosis of 
microbial keratitis, corneal dystrophies and degenerations. The technique allows 
microscopic analysis of the cornea layer by layer and detailed assessment of kerato-
cytes and inflammation cells. Features characteristic for HSV-1 keratitis depending 
on the stage and form include: microerosions, distortion of the superficial and basal 
epithelium, changes in superficial epithelial cell density, increase in epithelial cell 
size, squamous metaplasia, subepithelial infiltration of highly reflective dendritic 
Figure 4. 
Representative images of the slit-lamp photograph of the different forms of HSV endothelitis. (A, B, C, D) The 
slit lamp photographs of the eye of a 34-year old patient with recurrent, excessive endothelitis with significant 
corneal edema and Descemet folds. (A, B) At baseline. Diffuse corneal edema with Descemet folds and 
punctate keratopathy. Patient treated with the combination of antiviral medication (oral acyclovir 800 mg, 5 
times daily at baseline combined with 0,1% dexamethasone (7 times daily) and preservative free lubricant eye 
drops (5 times daily). (C, D) At 2 months in the course of treatment. Significant decrease in stromal edema, 
with only subtle stromal haze. Improvement of the punctate epitheliopathy. (E) Distinct area of the corneal 
edema - disciform endothelial keratitis. (F) Distinct area of the corneal edema - disciform endothelial keratitis 
at retroillumination. Ghost, profound vessels visible.
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structures (correspondind to Langerhans cells), keratocytes activation, sub-basal 
nerve plexus alteration or absence, stromal fibrosis and endothelial precipitates. 
Figure 6 presents the example of confocal microscopy results in case of patients 
with HSV keratitis. Confocal microscopy could guide in the disease diagnosis and 
monitoring the treatment results. In patients with stromal involvement the mean 
subbasal nerve density was proved to be significantly lower compared to healthy 
eyes. Also, in patients qualifying for surgical interventions, the technique has a 
potential role in assessing the sub-basal nerve plexus anatomy, helping the surgeons 
to procced with intervention decisions. The prognosis of patients with significantly 
altered corneal nerve plexus is poor after traditional transplant surgery [13–16].
3.4 Optical coherence tomography
Anterior eye segment imaging with 830 nm optical coherence tomography (AS 
OCT) was first demonstrated and published in 1994. Changing the light wave-
length from 830 nm to 1310 nm allowed the direct transcleral anterior eye segment 
structures including trabecular-iris angle visualization in 2000. OCT provides in 
vivo anterior eye segment imaging with the axial resolution from 18 μm with time 
domain OCT (TD OCT) to 5 μm with spectral domain OCT (SD OCT) and to 5 μm 
with ultra high resolution spectral domain OCT. OCT is proven to provide reliable 
anterior eye segment morphology and morphometry results with high reproduc-
ibility and repeatability. Application of OCT in herpetic keratitis patients include: 
assisting in diagnosis of patients at active stage and assessing the scars in patients 
qualified for laser or surgical interventions. Active keratitis could be characterized 
Figure 5. 
Representative images of the slit-lamp photograph of the different forms of neurotrophic keratitis.  
(A) Neurotrophic keratitis stage 2. A nonhealing corneal persistent epithelial defect (PED) after 
fluorescein installation. (B) A single, central corneal ulcer with stromal infiltration and peripheral corneal 
vascularization. (C) Central corneal perforation in the course of the corneal thinning and scarring and 
vascularization. (D) Neurotrophic keratitis stage 3. Neurotrophic ulceration with elevated borders and 
significant stromal haze.
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by the presence of the ulceration, stromal edema and inflammatory hyperreflective 
infiltrates. Corneas with inactive keratitis are characterized by stromal scarring 
and thinning, and epithelial remodeling [17–22]. Characteristic OCT features are 
presented in the Figure 7.
3.5 Laboratory testing
There are several laboratory techniques, which may help in the diagnostic pro-
cess. Clinical samples for the analysis may be obtained through collection of tears, 
corneal epithelial cells, and conjunctival cells. Tear samples are usually obtained 
using Schirmer test. Epithelial or conjunctival cells may be collected through 
corneal scrapings, corneal impression membranes (CIM) or using conjunctival or 
corneal swab. The less invasive the technique the lesser probability of obtaining a 
clinically detectable material.
The isolation of the HSV from the cornea and performing a viral culture remains 
a conventional, gold standard technique, however the main disadvantages of this 
methods are low sensitivity and a time consuming process. Giemsa staining of the 
epithelial corneal cells may visualize multinucleated giant cells, resulting from 
coalescence of HSV infected epithelial cells and intranuclear HSV inclusions. 
Immunofluorescence assay (IFA) is one of the modern techniques developed to 
diagnose HSV keratitis. The principle of the method is to introduce antibodies, that 
bind to HSV antigens specifically to gain fluorescence based immunological detec-
tion of HSV-1 antigen through color visualization under microscopy. Disadvantages 
of the method include: required subjective interpretation by an experienced techni-
cian and the risk of obtaining false positives results due to cross-reactivity between 
other microorganisms.
Figure 6. 
Representative images of the confocal microscopy scans revealing significant features characteristic for HSV 
keratitis. (A) Epithelial, healed dendritic ulcer with noticeable fibrotic borders (arrows). (B) Multiple 
infiltration of small dendritic structures as the level of the epithelium. Clusters of inflammation cells (arrows). 
(C) Multiple infiltration of pronounced dendritic cells forming a lattice pattern (arrows) at the level of the 
basal epithelial cells. (D) Marked fibrosis at the level of the Bowman layer (arrow) with inflammation cells 
infiltration (stars). (E) Excessive fibrosis and inflammation cells infiltration forming clusters at the level of the 
Bowman layer (arrows). Dendritic structures visible (star). (F) Anterior stromal keratocytes activation with 
accompanying haze (arrow). (G) Stromal infiltration and haze accompanied by multiple crystalline structures 
due to the lipid degeneration (stars). (H) Multiple endothelial opacities. Examples marked with stars.
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Advanced diagnostic techniques include: Polymerase Chain Reaction (PCR) - 
conventional PCR, reverse transcriptase PCR (RT-PCR), real-time PCR (qPCR) 
and multiplex PCR. qPCR overcomes the disadvantages of conventional PCR by 
acquiring more rapid and sensitive results. Guda SJM. et al. assessed sensitivity and 
specificity of the conventional and real-time PCR compared to IFA performed on 
corneal scrapings. The sensitivity and specificity of conventional PCR was 100% 
and 76.9% and 100% and 28.2% of qPCR respectively. Satpathy et al. assessed and 
concluded, that specificity and positive predictive value (PPV) of PCR was higher 
in tear (90.6% and 37.5%). compared to cornea scrapings (71.3% and 30.3%). 
Moreover, Akbarian A. et al. reported, that conventional PCR with added internal 
amplification control (IAC) had higher sensitivity (100%) vs. culture method 
(66.66%), while the specificity was 100% for both diagnostic methods.
Also novel methods, such as multiplex dot hybridization (MDH) assay, immu-
nochromatographic assay (ICGA, AmpliVue) or Infected cell protein 0 (ICP0) 
detection in tears are either tested or incorporated into a clinical practice. AmpliVue 
is a commercially available immunochromatographic assay, office-based diagnostic 
test characterized by a 64.7% positive detection rate. Sensitivity and specificity of 
AmpliVue was assessed as 84% and 100% respectively, based on true positives from 
culture and PCR combined. The MDH assay is a rapid technique, that involves a series 
of oligonucleotide probes specific for HSV genes. Compared to the real-time PCR, 
the MDH assay is characterized by very high values of sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) of 93.3%, 100%, 100% 
and 98.4%, respectively. The infected cell protein 0 (ICP0) is an acute phase protein 
during HSV infection and plays a significant role in the virus gene expression activa-
tion. ICP0 could be potentially defected in tears of affected subjects [23–28].
4. Differential diagnosis
Differential diagnosis is dependent on the corneal layer affected by the kera-
titis. Epithelial keratitis should be differentiated with epithelial regeneration line 
Figure 7. 
Representative images of the anterior segment swept source optical coherence scans revealing significant 
features characteristic for HSV corneal scars. (A) Slit lamp photograph of the central post herpetic keratitis 
scar. (B) High resolution scan. Hyperreflective tissue within corneal stroma with irregular borders (arrows). 
(C) Pachymetry map. Marked paracentral corneal thinning to 398 μm. (D) Slit lamp photograph of the 
central post herpetic keratitis scar. (E) High resolution scan. Hyperreflective tissue within corneal stroma with 
irregular borders. Note the relatively smooth corneal surface and epithelial compensation over the irregular 
corneal stroma (arrows). (F) Pachymetry map. Marked irregular, paracentral corneal thinning to 382 μm.
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after traumatic epithelial defect, epithelial corneal dystrophies, such as epithelial 
basement membrane corneal dystrophy (EBMCD; map-finger-dot dystrophy, 
Cogan microcystic dystrophy), epitheliopathy associated with excessive contact 
lens wear or iatrogenic epitheliopathy after topical drops containing preserva-
tives. Stromal involvement requires differentiation with other microbial keratitis 
(bacterial, fungal or amoebic), vaccinia virus keratitis (VACVK), Varicella Zoster 
virus keratitis, Thygeson superficial punctate keratopathy, stromal or Bowman 
layer corneal dystrophies, such as TGFBI corneal dystrophies. Marginal keratitis 
should be differentiated with other forms of marginal ulcers, such as staphylo-
coccal marginal keratitis or related to atopic or autoimmune diseases, such as 
rheumatoid arthritis, systemic lupus or granulomatosis with polyangiitis (GPA). 
Also, neurotrophic keratitis may be initiated by multiple other causes, such as 
surgical and laser procedures, chemical burns, excessive contact lens wear and 
preservative-containing topical medicines, diabetes mellitus, multiple sclerosis 
and congenital or acquired abnormalities of the trigeminal nerve. Examples of the 
diseases, which require differential diagnosis with HSV keratitis are presented in 
Figure 8.
Figure 8. 
Representative images of the slit-lamp photograph of the different forms of corneal diseases, which should be 
differentiated with HSV-keratitis. (A) Slit-lamp photograph of the epithelial basement membrane corneal 
dystrophy (EBMCD; map-finger-dot dystrophy, Cogan microcystic dystrophy). Superficial white dots visible. 
(B) The slit lamp photograph after fluorescein installation under blue light with additional yellow barrier 
filter of the patient 9A. An irregular area of the disrupted epithelium visible. (C) Slit-lamp photograph of 
the lattice corneal dystrophy (LCD). A dystrophy was confirmed by the TGFBI gene testing, which revealed 
a H626R mutation. (D) Slit-lamp photograph of the pediatric form of the lattice corneal dystrophy (LCD). 
Epithelial haze with multiple small, gray dots is visible. A dystrophy was confirmed by the TGFBI gene testing, 
which revealed a R124C mutation.
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5. Management
Major advances in the treatment of HSV keratitis have been provided by the 
evidence-based results and conclusions of the Herpetic Eye Disease Study (HEDS) 
randomized clinical trials, which were multicenter, characterized by double-
masking with placebo controls studies. Based on this knowledge, further treatment 
guidelines were proposed and published [12, 29–37]. Although the HEDS clinical 
trials directly addresses multiple clinical concerns, the studies have also several 
limitations. These include: inadequate sample size in case of HSV stromal keratitis 
with epithelial ulceration to determine the optimal course of therapy, relatively high 
rate of follow up failure within the study group. Also, the corticosteroid regimen 
was standardized and fixed in the study group, thus lacking the evidence of benefit 
of delivery of personalized care. Finally, the concerns regarding the dose and the 
optimal period of antiviral prophylaxis have not been resolved.
5.1 Active keratitis
Nowadays, the main treatment line of the active keratitis is a combination of 
the antiviral and corticosteroids drugs, depending on the epithelial and stromal 
involvement. The general rule to follow is to avoid corticosteroids in epithelial 
keratitis, because the entity of this form is virus activation and to treat with cor-
ticosteroids in stromal and endothelial keratitis without epithelial involvement, 
because those forms are strongly connected with the significant reaction of the 
immune system.
Antiviral drugs are used in two main forms: topical and oral. Topical anti HSV-1 
drugs include: trifluridine solution (1%), ganciclovir gel (0.15%), and acyclovir oint-
ment (3%). Oral anti HSV-1 drugs include: acyclovir, valacyclovir, and famciclovir. 
Historically, other systemic drugs were also used, such as idoxuridine, vidarabine, 
valganciclovir, foscarnet, and cidofovir, but they were withdrawn from the market 
or are relatively too toxic in combination with the achieved therapeutic effect.
Most common antiviral drug worldwide is acyclovir used either orally or 
topically or in combination. Common side effects of the prolonged oral acyclovir 
include nausea, vomiting, diarrhea, headache and weakness. Potentially serious, 
but very rare side effects include renal failure and hematology complications, such 
as: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syn-
drome (HUS).
In recent years, there have been an increasing interest in valacyclovir, due to its 
proven improved bioavailability and steadier plasma concentration compared to 
acyclovir. Valacyclovir is considered a prodrug of acyclovir. The lower frequency of 
dosing (2 times daily versus 5 times daily) may be a strong benefit for some patients. 
However, there is a lack of strong evidence, that treatment with valaciclovir pro-
vides leads to better results and less ocular and systemic complications. Comparing 
to herpes zoster ophthalmicus, the authors of the systematic Cochrane report 
indicated uncertainty of the relative benefits and harms of valacyclovir over acy-
clovir [38]. All topical antiviral drugs are characterized by ocular surface toxicity, 
could cause allergic reactions, and punctal and nasolacrimal duct stenosis, therefore 
the prolonged usage of those formulas is not advised. Authors of the Cochrane 
systematic review on HSV keratitis treatment, published in 2015 also assessed other 
methods of HSV keratitis treatment, such as manual debridement of the corneal 
epithelium or experimental biologic agents. Manual debridement alone has been 
proved to be not effective. Also, topical treatment with interferon has only a modest 
benefit over placebo [39]. In case of epithelial keratitis, the mainstay of treatment 
is antiviral agents. Corticosteroids excessive usage may lead to geographical ulcers 
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and delay healing of the epithelium. When stromal involvement is present, the 
mainstay of treatment is the use of corticosteroids with the combination of antiviral 
agents. The HEDS clinical trials have brought solid rationale for the treatment of the 
stromal keratitis with corticosteroids. Nowadays, there are several available topical 
corticosteroids formulas with different anti-inflammatory potency and different 
potential for adverse reactions: Dexamethasone 0,1%, Betamethasone at concentra-
tions ranging from 0.01% to 0.1%, Prednisolone 1%, Loteprednol Etabonate 0.5%, 
Rimexolone 1%, Dexamethasone 0.1%, Hydrocortisone 0.335%, Fluorometholone 
0,1%. The strongest anti-inflammatory effect is demonstrated by dexamethasone, 
the weakest by hydrocortisone. This should be taken into consideration, when 
choosing the medication depending on the level of the corneal inflammation. 
Moreover, steroid medication must be withdrawn gradually, tapering the doses 
generally over few weeks’ time. During the drug withdrawal, instead of sudden 
discontinuation of the stronger corticosteroid, one may consider replacing it with 
a relatively weaker one to avoid a rebound increase in inflammation and a disease 
recurrence immediately after drug cessation. The recommended treatment for HSV 
stromal keratitis without ulceration should include a topical corticosteroid for at 
least a period exceeding ten weeks in conjunction with a prophylactic oral antiviral. 
A treatment period greater than ten weeks has been recommended, because of the 
high treatment failure rates six weeks after a ten-week prednisolone taper in the 
HEDS clinical trial. The most concerning side effects of topical steroids include: 
increase of the intraocular pressure, cataract and secondary infections (including 
bacterial, fungal, and also viral infections). Therefore, patients must be monitored 
carefully when treating with topical steroids.
5.2 Recurrence prevention
The HEDS study on recurrence rate clearly demonstrated that short-course oral 
during an active HSV epithelial keratitis does not prevent later stromal keratitis or 
iritis. On the other hand, a 12-month course of prophylactic oral acyclovir (400 mg) 
twice daily significantly decreased a recurrence rate of the stromal involvement. 
Although the HEDS study authors did not recommend a prolonged, beyond 
12 months acyclovir prophylaxis, clinical practice recommendations and observa-
tions seem to postulate a positive role of a long-term prophylaxis, especially in 
patients with a high recurrence rate, significant corneal thinning at risk of corneal 
perforation, with comorbidities, such as atopy, autoimmune diseases or in immu-
nocompromised patients. Also patients with history of HSV keratitis undergoing 
surgical procedures, such as corneal transplant, photorefractive procedures or cata-
ract surgery may benefit from acyclovir prophylaxis, until the level of inflammation 
associate with the procedure and the risk of recurrence is decreased [12, 29–37].
One of the future treatment strategies is to enhance patient’s immune system 
resistance to the infection through a vaccine against HSV-1. Nowadays there are no 
approved vaccine available, but there are ongoing studies regarding this subject. 
In the recently published study in 2020, the authors identified 15 viral-encoded 
proteins, which could serve as candidates for further testing for the HSV-1 
 vaccine [40].
5.3 Neurotrophic keratitis
There are several methods of treatment depending on the severity level 
of keratitis. First line therapy includes discontinuing potentially toxic topical 
medications, tear replacement products and oral supplementation with omega-3 
fatty acids. The next step of treatment is immunomodulatory therapy including: 
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lifitegrast, cyclosporine and steroids at different frequency and concentrations, 
and also autologous serum eye drops at concentrations from 20–100%. Autologous 
serum eye drops are characterized by multiple benefits: biochemical characteris-
tics, including pH, nutrient content, vitamins, fibronectin, growth factors such as 
epithelial growth factor (EGF) or nerve growth factor (NGF), are similar to that of 
human tears, the serum eye drops also inhibit the release of inflammatory cytokines 
and increase the number of goblet cells and mucin expression in the conjunctiva. 
Prolonged use of serum eye drops is proved to restore homeostasis of the ocular 
surface.
In the last few years, there have been an increasing interest in the implementa-
tion of the Nerve Growth Factor (NGF) in the sub-basal nerve plexus regeneration, 
leading to the complete healing of the neurotrophic ulcers. NGF is an endogenous 
protein involved in the differentiation and maintenance of all systemic neurons, 
while in corneal tissue it is established to play a role in corneal innervation, tear 
secretion mechanism, and corneal epithelial cell growth and stability. Cenegermin 
is a recombinant human Nerve Growth Factor (rhNGF) that is structurally identi-
cal to the human NGF protein made in ocular tissues, it was introduced in the 
ophthalmic solution at concentration of 0.002% (20 mcg/mL). Two controlled 
clinical trails in Europe (REPARO) and USA (NGF0214) provided strong evidence 
on its effectiveness. 72% and 65% of patients with neurotrophic keratitis receiving 
cenegermin were completely healed in Europe and USA trails respectively [41–44]. 
Matrix regenerating agent (ReGenerating Agent; RGTA), mimicking natural hepa-
ran sulfate within the corneal tissue, is also a recent topical agent showing promis-
ing results in the treatment. RGTA eye drops (Cacicol; Thea) are preservative-free, 
well-tolerated, proved to promote regeneration of damaged tissues and to enhance 
corneal tissue healing [45, 46].
Novel emerging treatment approaches also include thymosine β4, CODA001, 
topical insulin, Substance P and insulin-like growth factor 1 (IGF-1). Thymosine 
β4 and CODA001 are in the most advanced evaluation undergoing clinical trials. 
Thymosin beta 4 is a 43-amino acid peptide, a major constituent protein of mac-
rophages, and platelets. Currently, third-phase, multi-center, randomized, double 
masked, placebo controlled clinical study is ongoing regarding its role in ocular 
surface healing. Insulin at 3 different concentrations. CODA001 is an antisense 
oligonucleotide (antisense deoxynucleotide oligomer) that modulates and down-
regulates the expression of the gap junction protein Cx43 (Connexin-43), which is 
increased in persistent epithelial defects [47].
Other procedures implemented at different severity levels of neurotrophic 
keratitis include: therapeutic contact lenses, lacrimal punctual occlusion, amniotic 
membrane contact lens or transplantation, partial or complete tarsorraphy, corneal 
transplant, conjunctival flap transplant or direct neurotization.
Amniotic membrane transplantation (AMT) is proved to provide many benefits 
in the treatment of neurotrophic keratitis. AMT inhibits the activity of inflamma-
tory cells, extends the life of corneal epithelial stem cells and maintains their ability 
to regenerate epithelial cells, promotes healing of the corneal wounds, blocks the 
TGF-ß cytokine system activation and the transformation of fibroblasts into myo-
fibroblasts, also creates a protective membrane covering the affected ocular surface 
tissues. In dry eye disease, it is used in case of serious complications, such as corneal 
ulcer or microperforation. An interesting solution to consider is a sutureless, adhe-
siveless amniotic membrane transplant (AMT; ProKera; Bio-Tissue, Inc.) implanta-
tion. It is a corneal–epithelial device that consists of a polycarbonate ring conformer 
containing cryopreserved amniotic membrane. Advantages of this design include: 
shorter surgical time and prevention of suture-related complications [48].
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To summarize neurotrophic keratitis treatment: a stepwise approach should 
be implemented with careful exclusion of the active infection. Topical treatments 
should be the first line therapy over the surgical interventions.
5.4 Surgical interventions
Surgical interventions in active HSV keratitis are limited to the severe stromal 
involvement with the increased risk of corneal perforation. Those may include: 
application of cyanoacrylate glue, amniotic membrane transplantation or therapeu-
tic keratoplasty.
Other indications for surgical procedures include inactive corneal scarring 
after keratitis or cataract formation mainly due to prolonged treatment with 
topical steroids. Superficial opacifications could be considered as an indication 
for phototherapeutic keratectomy (PTK), although the corneal thinning is usual 
after HSV keratitis and therefore it limits the use of this method. The PTK abla-
tion should always be limited to anterior one-third of stromal layers and leave 
a minimum residual stromal bed thickness (RSBT) of 250 μm to avoid further 
corneal ectasia. Also, spontaneous reactivation of HSV keratitis is well known 
after PTK, because laser ablation stimulates viral shedding in tears and reactivates 
the virus [49, 50].
When an extensive scar with corneal thinning is present a deep anterior lamellar 
keratoplasty (DALK) or penetrating keratoplasty (PK) should be considered. DALK 
eliminates the risk of endothelial immunologic rejection, but due to advanced cor-
neal scarring and thinning may be difficult to perform. An obligatory preoperative 
assessment before keratoplasty procedures include the corneal sensitivity analysis 
and the exclusion of the active viral infection with neovascularization. It is well 
established, that the presence of deep stromal vascularization exceeding 2 or more 
quadrants, creates a significant risk for a graft immunologic rejection and graft 
failure. Another factor, strongly connected to the increased risk of the graft failure 
is a herpetic infection recurrence. To address those issues, the combination of the 
antiviral prophylaxis with the prophylaxis of a immunologic rejection should be 
implemented. Antiviral prophylaxis includes the use of high-dose oral acyclovir as 
recommended by American Academy of Ophthalmology (AAO guidelines recom-
mended 800 mg 3 times daily for at least 1 year) [37]. The prophylaxis of a immu-
nologic rejection includes usually systemic steroids combined with topical therapy. 
Despite the prophylaxis, there is a relatively high rate of graft failure performed in 
eyes after herpetic keratitis reported in the literature: 26% at 3 years, 15% at 5 years 
and 53.7% at 8 years [51–53]. In the last years, there have been an increasing interest 
in keratorosthesis surgery, as a viable option allowing a long term restoration of 
vision in patients with high risk for corneal transplantation. Boston type I kerato-
prosthesis (BKPro) is the most commonly implanted keratoprosthesis worldwide. 
BKPro was first used in 1965 by Professor Claes H. Dohlman [54, 55]. The BKPro 
surgery is usually complex with the high incidence of intraocular complications. 
Also the rate of postoperative complications is high and includes: glaucoma, 
retroprosthetic membrane formation, keratolysis, endophthalmitis, vitreoretinal 
complications, such as retinal detachment, cystoid macular edema, uveitis and 
hypotony/phthisis. In the latest study of the long term BKPro outcomes published 
in 2020, the probability of maintaining or improving vision was 75,0% at 5 years 
and 66,7% at 10 years [56].
In summary, surgical intervention in HSV keratits is challenging and high-risk 
procedure, therefore a special attention should be brought when referring such 
patients.
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6. Conclusions
HSV keratitis due to its multiform occurrence remains a challenging diag-
nostic in clinical practice. Modern imaging technique, such as optical coherence 
tomography or confocal microscopy as well as modern laboratory testing including 
multiplex dot hybridization (MDH) assay, immunochromatographic assay (ICGA, 
AmpliVue) are useful in guiding the diagnostic process.
Ocular surface homeostasis should be always considered when treating HSV 
keratitis, especially in the neurotrophic keratitis at different severity grades.
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